Eli Lilly

Lauren Chapman / IPB News

The political action committee of Indianapolis-based Eli Lilly, LillyPAC, has joined other major corporations in pausing political donations to some politicians after last week’s insurrection at the capitol. 

Eli Lilly's Corporate Headquarters in Indianapolis. The company announced initial findings from Phase 2 of the COVID-19 antibody treatment showing a reduction in hospitalizations.Credit Lauren Chapman / IPB NewsEdit | Remove

Indianapolis-based Eli Lilly announced Wednesday its COVID-19 antibody drug is showing results in reducing hospitalizations from the virus. This is the company’s first data to be reported on mild to moderate cases but still needs to be reviewed by peers.

Lauren Chapman / IPB News

Indianapolis-based Eli Lilly is moving to Phase 3 testing of a treatment to prevent COVID-19 after initial success. The next step will be to test the drug at nursing homes where the pandemic has hit hard.

Justin Hicks

Indiana hopes to at least double its COVID-19 testing capacity in the next month through a new partnership between the state, Eli Lilly and the Indiana Hospital Association.

Lauren Chapman / IPB News

Eli Lilly announced a new program Tuesday that caps the out-of-pocket costs for most insulin users at $35 a month. The Indianapolis-based company says it’s designed to help diabetes patients during the novel coronavirus crisis. 

Jill Sheridan / WFYI

The Lilly Endowment is giving Indiana organizations millions of dollars in grants in response to the novel coronavirus pandemic.

Paul Sableman / Wikimedia Commons

Indianapolis-based Eli Lilly and Company Tuesday expanded free COVID-19 testing to first responders in addition to health care workers.

Indiana reports 5 more coronavirus deaths for 12 total

Mar 24, 2020
Michael Conroy / AP Photo

INDIANAPOLIS (AP) — Five more deaths have been reported in Indiana from the coronavirus-related illness, giving the state a total of 12 as a statewide stay-at-home order is about to take effect.

The Indiana State Department of Health reported Tuesday that the number of confirmed COVID-19 cases grew by 107 to reach a total of 365 across the state.

Eli Lilly Announces Two Discounted Insulin Pens

Jan 14, 2020

Eli Lilly announced plans Tuesday to offer less expensive versions of two of the company’s insulin pens, eight months after introducing a reduced-price liquid insulin. 

Rule To Include Drugs Prices In Ads Challenged

Jun 18, 2019

Indianapolis-based Eli Lilly is challenging a new federal rule that would require drug companies to include prices in TV ads.

Reducing high drug prices is one of President Donald Trump’s priorities, and the move for more transparency through advertising was announced last year. 

New High Tech Microscope Coming To Indiana

Apr 16, 2019
The Thermo Scientific Krios G3i Cryo Transmission Electron Microscope. The microscope will be housed on Purdue’s campus in the CryoEM facility at the Wayne T. and Mary T. Hockmeyer Hall of Structural Biology. (Photo courtesy of Thermo Fisher Scientific)
Jill Sheridan

Six Indiana organizations have pitched in to buy a new high-tech microscope. The nearly $9 million machine is a cryo-electron microscope that allows scientists to examine molecules at the atomic level.

Purdue University Professor of Biological Sciences Richard Kuhn says a sample is taken and immersed in liquid nitrogen. 

Indianapolis-based drug company Eli Lilly says it will soon start selling a cheaper insulin for diabetic patients. The move comes amid outcry over high drug prices.

Eli Lilly Acquires New Cancer Treatment Drugs

May 14, 2018

Within in one week, Indianapolis-based Eli Lilly hopes two oncology purchases will boost its cancer drug portfolio.

Eli Lilly has purchased two smaller companies in the past week that have oncology drugs in development. The Indianapolis-based company hopes the investments boost its cancer drug portfolio.

Last week Eli Lilly announced a $1.6 billion buyout of California-based ARMO BioScience for an immunotherapy drug. Immunotherapy treatments – which train the body to fight disease – have gained momentum recently.

Mackenzie Fields, Dan Meno and Eryn Ruder hold signs on the street across from Eli Lilly prior to the shareholder meeting. Fields illustrated all three of the signs. (Samantha Horton/IPB News)
Samantha Horton

A small group of advocates stood on the sidewalk facing Eli Lilly’s headquarters in downtown Indianapolis Monday holding neon signs asking for an explanation of skyrocketing insulin prices.

There T1International and People of Faith for Access to Medicines organized the gathering before Nicole Smith-Holt went inside to deliver a statement.

Eli Lilly CEO Dave Ricks announces new diabetes pilot project. (Jill Sheridan/IPB News)
Jill Sheridan

A new partnership aims to reduce diabetes in three neighborhoods in Indianapolis where the rates of the disease are as high as 17 percent. The effort builds on work Eli Lilly and Company has developed in Mexico, South Africa and India.

Eli Lilly and Company CEO Dave Ricks says the $7 million, five-year effort will focus on three communities in Indianapolis. 

Partnership Offers Rides To Alzheimer's Trials

Apr 10, 2018

Alzheimer's scientists say they can't find a cure if they can't do the research, and they can't do the research if they don't have volunteers.

One of the biggest challenges for clinical trial participants is transportation. A new partnership aims to provide rides for volunteers in a new Eli Lilly study in Indianapolis and other locations across the country.  

Lilly Migraine Drug One Step Closer To Market

Dec 11, 2017

A new pain medication, part of Indianapolis-based Eli Lilly’s non-opioid pain management platform, took another step forward.

The drug is called galcanezumab. It’s one of three being crafted by Eli Lilly to treat chronic and serious pain. The medicine has shown promising results in a series of trials says Dr. Robert Conley, Lilly global development leader for migraine.

“Around 60 percent of our patients lost more than half of their headache days and some patients even got to 100 percent loss of headache,” says Conley

Azar Nominated For HHS Secretary

Nov 13, 2017

President Donald Trump announced the nomination of a former Eli Lilly executive as Health and Human Services Secretary Monday. Alex Azar is the latest Hoosier headed to Washington for a post in the federal health sector.

At Indianapolis-based pharmaceutical giant Eli Lilly, 2,300 employees will take buyouts as part of the company’s effort to save money by cutting at least 2,000 jobs in the U.S. by the end of the year.

It’s unclear whether layoffs are still in the works in the Hoosier state.

Lilly said in September it would aim to save $500 million by cutting 3,500 jobs out of its more than 41,000 worldwide, with at least 2,000 cut in the U.S.

Another Hoosier Health Leader Could Be Headed To D.C.

Oct 18, 2017

There are reports a former Eli Lilly leader tops the list of names President Donald Trump is considering to fill the position of Health and Human Services Secretary. Alex Azar would replace Tom Price, who left the job last month after a private plane scandal.

Azar would the take over the country’s highest health position if chosen, following a string of others leaving Indiana for the U.S. government’s health sector.

More than half a million Hoosiers have been diagnosed with diabetes, and many of them rely on insulin to live healthy lives. But patients say the skyrocketing price of the medicine —which more than doubled from 2002 to 2013 — is squeezing them to the point of outrage.

The Indiana University School of Medicine is getting $25 million from the Lilly Endowment to recruit new scientists to Indiana, and to pair them up directly with big Indiana companies.

Medical school research dean Anantha Shekhar says it aims to fast-track the creation of treatments from discoveries about cancer, diabetes, Alzheimer’s and more.

He says new technologies like gene sequencing are facilitating those applications faster than ever.

Eli Lilly is partnering with Pfizer to help develop a new drug that could be the first of a new class of non-opioid pain medications.

There hasn’t been a new pain medication discovery in about 50 years. The last new non-opioid pain medication to hit the market was ibuprofen in the late 1960s.

That’s a problem, because Indiana University Health’s Daniel Rusyniak says when it comes to the treatment of chronic pain we need more options.

22dd5d5b-0d1d-4b22-897d-6b8e2e4d469f
Eli Lilly / https://www.lilly.com/newsroom

Indianapolis-based Eli Lilly has been dealt another blow by the U.S. Food and Drug Administration, which failed to approve a newly-developed treatment for rheumatoid arthritis.

In what is referred to as a “complete response letter,” The FDA stated it wants Lilly to supply more data to clarify safes dosage levels and put certain safety concerns to rest.

a870b3a6-1142-48de-9670-f7d7bdaa3e7f
Raymond Gilford / https://www.flickr.com/photos/shuttercat7/

Indianapolis-based Eli Lilly, along with two other European pharmaceutical companies, is facing a price-fixing lawsuit regarding its rapidly escalating insulin prices. Lilly makes a form of insulin called Humalog, whose list price has doubled since 2011, the lawsuit claims.